FAP-targeted radiopharmaceuticals potential as next-gen treatment for multiple cancers

2026-06-18T11:44:00

fibroblast concept

Source:

Innovative radiopharmaceuticals demonstrated “highly promising” survival benefit in study of participants with end-stage solid tumours.

A novel radiopharmaceutical therapy targeting fibroblast activation protein (FAP) has demonstrated potent anti-cancer activity across 21 different types of advanced metastatic solid tumours, results from an early-phase trial show.

The study assessed treatment response and survival in 88 patients given either 177Lu-, 90Y-, or 225Ac-3BP-3940 FAP radiopharmaceutical therapy. According to Baum et al., “the observed survival benefit appears to be highly promising”. The treatments were well tolerated and enabled a median overall survival of…

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

  • Unlimited access to industry intelligence that can make a difference to your business
  • A weekly newsletter keeping the most vital information at the front of your thinking
  • Exclusive invitations to powerful webinars and events featuring high profile experts
  • Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member